Clinical Trial Update: Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19 [Phase 2]

View source ↗

Summary

Phase 2 trial update on nintedanib for pulmonary fibrosis in moderate to severe COVID-19 patients assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Huilan Zhang | Conditions: COVID-19, Nintedanib | Phase 2 | Status: UNKNOWN